CS-747S clinical pharmacology study

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080221011

Enrollment

100

Registered

2010-02-18

Start date

2010-03-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic Stroke (exclude cardiac cerebral embolism)

Interventions

investigational material(s) Generic name etc : CS-747S (Prasugrel) INN of investigational material : prasugrel Therapeutic category code : 339 Other agents relating to blood and body fluides Dosage an

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria At the time of informed consent signature, -The most recent ischemic stroke: 4 weeks or more -Age: Between 20 and 74 years old -Body weight: > 50kg (screening period) -Patients on clopidogrel (75mg/day) for 2 weeks or more (exclude patients with concomitant use of aspirin)

Exclusion criteria

Exclusion criteria: -Modified Rankin Scale grade 5 or more -Cardiac cerebral embolism, or cardiovascular disease cause of cardiac cerebral embolism (atrial fibrillation, patent foramen ovale, etc.) -Concomitant administration of clopidogrel and aspirin for secondary prevention of ACS etc. -Have active or prior history of intracranial hemorrhage -Have bleeding disorder or bleeding diathesis

Design outcomes

Primary

Measure	Time frame
pharmacodynamics -PRI value (VASP) -PRU value and % Inhibition (VerifyNow System)	—

Secondary

Measure	Time frame
safety pharmacokinetics pharmacogenomics -Plasma concentration of active metabolite -Adverse event, Bleeding event	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026